Jiaying Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiaying Liu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hui Zhang
School of Pharmacy Faculty of Medicine Macau University of Science and Technology Macau 999078 China must.edu.mo
1 shared publication - Jibo Hu
Department of Radiology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China
1 shared publication Na Li
Department of Radiology The Fourth Affiliated Hospital of School of Medicine and International School of Medicine International Institutes of Medicine Zhejiang University Yiwu 322000 China zju.edu.cn
1 shared publication- Yuchao Sun
The Core Facilities The Fourth Afliated Hospital of School of Medicine and International School of Medicine International Institutes of Medicine Zhejiang University Yiwu 322000 China zju.edu.cn
1 shared publication Zhiming Cui
Department of Radiology The Fourth Affiliated Hospital of School of Medicine and International School of Medicine International Institutes of Medicine Zhejiang University Yiwu 322000 China zju.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2026 (1) , 6970441
Nebulized Lycopene Attenuates Radiation‐Induced Pulmonary Inflammation and Fibrosis in Mice via Activating Nrf2/HO‐1 and Inhibiting TGF‐β1/Smad Signaling
The development of radiation‐induced lung injury (RILI) presents a major clinical challenge that limits the efficacy and safety of thoracic radiotherapy. This condition evolves from acute inflammatory damage to irreversible fibrotic remodeling, yet effective and targeted treatment options remain scarce. Lycopene, a potent dietary carotenoid predominantly found in tomatoes, possesses a multifaceted pharmacological profile encompassing antioxidant, anti‐inflammatory, and antifibrotic effects. The nebulized delivery of lycopene offers a direct route to the lungs, enhancing site‐specific action and reducing off‐target risks, which addresses a key need in managing RILI. This study explored the protective efficacy and mechanisms of nebulized lycopene in RILI. C57BL/6 mice subjected to 20 Gy thoracic irradiation received lycopene via nebulization as preventive and continuous treatment. BEAS‐2B and NIH‐3T3 cells were treated with irradiation and lycopene in combination with pharmacological inhibitors (ML385 and SB431542) or specific gene knockdown (siNrf2 and siTGF‐β1) to validate pathway dependency. Lung injury, inflammation, fibrosis, oxidative stress, and protein expression were detected by histology, ELISA, Western blot, immunofluorescence, and ROS detection. Lycopene dose‐dependently improved RILI mice’s survival, alleviated lung damage, inhibited inflammation at 4 weeks and fibrosis at 12 weeks, activated the Nrf2/Heme Oxygenase‐1 (HO‐1) pathway in BEAS‐2B cells, and suppressed the TGF‐β1/Smad pathway in NIH‐3T3 cells, with good safety. These findings suggest that nebulized lycopene attenuates RILI through differential modulation of epithelial Nrf2/HO‐1 signaling and fibroblast TGF‐β1/Smad signaling, supporting its candidacy as a dietary bioactive compound for radioprotection.
- 1 January 2026
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2026 (1) , 6970441
Open AccessNebulized Lycopene Attenuates Radiation‐Induced Pulmonary Inflammation and Fibrosis in Mice via Activating Nrf2/HO‐1 and Inhibiting TGF‐β1/Smad Signaling
The development of radiation‐induced lung injury (RILI) presents a major clinical challenge that limits the efficacy and safety of thoracic radiotherapy. This condition evolves from acute inflammatory damage to irreversible fibrotic remodeling, yet effective and targeted treatment options remain scarce. Lycopene, a potent dietary carotenoid predominantly found in tomatoes, possesses a multifaceted pharmacological profile encompassing antioxidant, anti‐inflammatory, and antifibrotic effects. The nebulized delivery of lycopene offers a direct route to the lungs, enhancing site‐specific action and reducing off‐target risks, which addresses a key need in managing RILI. This study explored the protective efficacy and mechanisms of nebulized lycopene in RILI. C57BL/6 mice subjected to 20 Gy thoracic irradiation received lycopene via nebulization as preventive and continuous treatment. BEAS‐2B and NIH‐3T3 cells were treated with irradiation and lycopene in combination with pharmacological inhibitors (ML385 and SB431542) or specific gene knockdown (siNrf2 and siTGF‐β1) to validate pathway dependency. Lung injury, inflammation, fibrosis, oxidative stress, and protein expression were detected by histology, ELISA, Western blot, immunofluorescence, and ROS detection. Lycopene dose‐dependently improved RILI mice’s survival, alleviated lung damage, inhibited inflammation at 4 weeks and fibrosis at 12 weeks, activated the Nrf2/Heme Oxygenase‐1 (HO‐1) pathway in BEAS‐2B cells, and suppressed the TGF‐β1/Smad pathway in NIH‐3T3 cells, with good safety. These findings suggest that nebulized lycopene attenuates RILI through differential modulation of epithelial Nrf2/HO‐1 signaling and fibroblast TGF‐β1/Smad signaling, supporting its candidacy as a dietary bioactive compound for radioprotection.